D-0544-2026 Class II Ongoing
FDA drug recall D-0544-2026 was initiated by Zydus Pharmaceuticals (USA) Inc on Apr 29, 2026 and is designated Class II. Reason for recall: CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit The recall status is ongoing. Affected quantity: 23,880 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- May 27, 2026
- Initiation Date
- Apr 29, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 23,880 bottles
Product description
Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; a) 30 count bottles (NDC 70710-1047-3); b) 100 count bottles (NDC 70710-1047-1).
Reason for recall
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Distribution pattern
Nationwide within the U.S
Code information
Lots: a) M411146, Expires: 08/2026; M502098, M502097, Expires: 01/2027; b) M411145, Expires: 08/2026.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0544-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026